Related references
Note: Only part of the references are listed.Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis
James P. Brodeur et al.
ARTHRITIS AND RHEUMATISM (2010)
Conjunctival Sac Fluid Contains Elevated Levels of Soluble TRAIL: Implications for the Anti-Tumoral Surveillance of the Anterior Surface of the Eye
Paola Secchiero et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2009)
Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome
David Haynes et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
The abundant synovial expression of the RANK/RANKL/osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation
Bernard Vandooren et al.
ARTHRITIS AND RHEUMATISM (2008)
Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin
Giorgio Zauli et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2008)
Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway
Estelle Chamoux et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
sRANKL and OPG in serum and synovial fluid of patients with rheumatoid arthritis in comparison to non-destructive chronic arthritis
Gert E. Hein et al.
RHEUMATOLOGY INTERNATIONAL (2008)
Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate
H. P. Sennels et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2008)
The imbalance between osteoprotegerin and cathepsin K in the serum of patients with longstanding rheumatoid arthritis
Martin Skoumal et al.
RHEUMATOLOGY INTERNATIONAL (2008)
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
Paola Secchiero et al.
BLOOD (2008)
TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27(Kip1) accumulation in pre-osteoclast precursors
Giorgio Zauli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2
Simone H. Mangan et al.
CARDIOVASCULAR RESEARCH (2007)
Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis
Yu Asanuma et al.
ATHEROSCLEROSIS (2007)
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Giorgio Zauli et al.
BLOOD (2007)
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats
Fabio Fischetti et al.
ARTHRITIS AND RHEUMATISM (2007)
Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis
Judith Auer et al.
ARTHRITIS RESEARCH & THERAPY (2007)
An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction
Paola Secchiero et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology
Giorgio Zauli et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Evaluation of classical complement pathway activation in rheumatoid arthritis - Measurement of C1q-C4 complexes as novel activation products
D Wouters et al.
ARTHRITIS AND RHEUMATISM (2006)
Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis
MA Hietala et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells
T Miyashita et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2004)
Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex
F Bossi et al.
JOURNAL OF IMMUNOLOGY (2004)
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF
G Zauli et al.
BLOOD (2004)
Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells
D Milani et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells
G Zauli et al.
CIRCULATION RESEARCH (2003)
High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment
M Ziolkowska et al.
ARTHRITIS AND RHEUMATISM (2002)
Local production of complement proteins in rheumatoid arthritis synovium
E Neumann et al.
ARTHRITIS AND RHEUMATISM (2002)
Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo
A Dobrina et al.
BLOOD (2002)
Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells
UM Malyankar et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
